Nimodipine (Nimotop)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Subarachnoid Hemorrhage

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 2 (8)
Subarachnoid Hemorrhage
NCT05131867 · Zagazig University
2021-11-24 – 2022-05-24 · Oral Nimodipine, Milrinone, Vascular Spasm After Traumatic Subarachnoidhaemorrhage
What this study did
Other / comorbidity
NCT06900998 · Yale University
2026-09-01 – 2032-06-30 · Alcohol Use Disorder
What this study did
NCT07681869 · Yale University
2026-09-01 – 2032-06-30 · Alcohol Use Disorder
What this study did
NCT04801953 · Medical University of Vienna
2021-05-04 – 2024-04-09 · Vestibular Schwannoma
What this study did
NCT04028596 · Rijnstate Hospital
2019-12-05 – 2023-04-15 · Epilepsy, Depression, Postictal Delirium, Electroconvulsive Therapy
What this study did
NCT03228498 · Azienda Ospedaliero-Universitaria Careggi
2017-05-02 – 2019-07-09 · Vascular Cognitive Impairment
What this study did
NCT01551368 · Mount Sinai Hospital, Canada
2012-12 – 2017-07 · Infertility
What this study did
NCT00000332 · National Institute on Drug Abuse (NIDA)
1998-05 – 2000-04 · Cocaine-Related Disorders
What this study did
Phase 1/2 (1)
Subarachnoid Hemorrhage
NCT01893190 · Edge Therapeutics Inc
2013-09 – 2016-01 · Ruptured Cerebral Aneurysm, Ruptured Berry Aneurysm
What this study did
Phase 1 (8)
Subarachnoid Hemorrhage
NCT02893826 · Edge Therapeutics Inc
2016-09 – 2018-03 · Subarachnoid Hemorrhage, Aneurysmal
What this study did
Other / comorbidity
NCT04923659 · University Health Network, Toronto
2021-05-25 – 2026-05 · Low Intensity Focussed Ultrasound
What this study did
NCT03671525 · Johns Hopkins University
2018-10-05 – 2023-05-12 · Schizophrenia, Schizo Affective Disorder
What this study did
NCT05182619 · Sohag University
2022-01-01 – 2023-04-01 · Traumatic Brain Injury
What this study did
NCT03794843 · Shenyang Dongxing Pharmaceutical Technology Co., Ltd.
2018-08-23 – 2019-06 · Bioavailability, Safety Issues, Ischemic Cerebrovascular Disease
What this study did
NCT01835665 · University of California, San Francisco
2013-03 – 2016-05 · Progranulin Mutation Carriers
What this study did
NCT00000280 · Yale University
1994-09 – 1999-08 · Cocaine-Related Disorders
What this study did
NCT00000738 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1994-06 · AIDS Dementia Complex, HIV Infections
What this study did
Phase 4 (4)
Other / comorbidity
NCT03150524 · Johns Hopkins University
2017-07-01 – 2019-05-31 · Reversible Cerebral Vasoconstriction Syndrome
What this study did
NCT02248233 · Fengtian Hospital
2014-10 – 2015-09 · Cerebral Infarction
What this study did
NCT01220622 · Ministry of Science and Technology of the People´s Republic of China
2010-10 – 2012-07 · Stroke, Mild Cognitive Impairment
What this study did
NCT00814658 · Janssen-Cilag Farmaceutica Ltda.
2008-06 – 2009-10 · Dementia
What this study did
Early phase / not applicable (7)
Subarachnoid Hemorrhage
NCT04309708 · B. Braun Medical International Trading Company Ltd.
2018-05-01 – 2019-09-08 · Subarachnoid Hemorrhage
What this study did
Other / comorbidity
NCT07048522 · University of Ioannina
2025-05-19 – 2027-02-15 · Colectomy, Open Surgery, Pain, Pain, Postoperative, Pain, Acute
What this study did
NCT06998368 · Hans-Peter Landolt
2024-10-22 – 2026-12 · Mediation of 5G Effects on Sleep
What this study did
NCT06007573 · Yuzhen Pan
2021-02-01 – 2023-08-15 · Post-stroke Dementia
What this study did
NCT02537080 · University Hospital Hradec Kralove
2015-09 – 2017-12 · Mild Cognitive Impairment
What this study did
NCT01672801 · Boston IVF
2012-09 – 2014-04 · Unexplained Infertility, Polycystic Ovarian Syndrome, Anovulatory
What this study did
NCT00004399 · FDA Office of Orphan Products Development
1995-09 – 2000-08 · Pre-eclampsia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Subarachnoid Hemorrhage
NCT02790632 · Edge Therapeutics Inc
2016-07 – 2018-06 · Subarachnoid Hemorrhage, Aneurysmal
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Early phase / not applicable (1)
Other / comorbidity
NCT06615882 · Yonsei University
2024-09 – 2027-04 · Intracranial Vasospasm
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Subarachnoid Hemorrhage
NCT04100824 · Assiut University
2020-01-11 – 2023-01-12 · Subarachnoid Hemorrhage
What this study did
NCT02165644 · University of Florida
2015-09 – 2015-09 · Acute Cerebrovascular Accident, Vasospasm
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Subarachnoid Hemorrhage: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nimodipine (Nimotop): this drugApprovedSmall moleculeL-type calcium channels (Cav1.2)not yet gradedNo reviewed efficacy summary in this indication
Nimodipine (GTx-104)Phase 3Small moleculeL-type calcium channels (Cav1.2)not yet gradedNo reviewed efficacy summary in this indication
Lercanidipine
—(overall)
Small moleculeL-type calcium channels (Cav1.2)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nimodipine (Nimotop) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicableColectomy, Open Surgery, Pain, Pain, Postoperative, Pain, AcuteRecruiting
Est. primary completion 2026-12-19 · NCT07048522 · CT.gov ↗
What to watch
2032 (2)
June 2032 (2)
Phase 2Alcohol Use DisorderNot yet recruiting
Est. primary completion 2032-06-30 · NCT06900998 · CT.gov ↗
What to watch
Phase 2Alcohol Use DisorderNot yet recruiting
Est. primary completion 2032-06-30 · NCT07681869 · CT.gov ↗
What to watch

See the full readout calendar ↗